Immune checkpoint inhibitors and cardiovascular toxicity Varricchi G, Marone G, Mercurio V, Galdiero MR, Bonaduce D, Tocchetti CG Curr Med…
anno pubblicazione 2018
-
-
Cardiovascular Toxicity in Cancer Survivors: Current Guidelines and Future Directions Cardio-Oncology Connection 07.16.2018 INTRODUCTION An individual…
-
Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors Varricchi G, Galdiero MR, Mercurio V, Bonaduce D, Marone G, Tocchetti CG Lancet Oncol. 2018…
-
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study Salem JE, Manouchehri A, Moey…
-
Doxorubicin-induced heart failure in cancer patients: A cohort study based on the Korean National Health…
-
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and…
-
BOOK AIOM: Cardio-Oncologia 2018 – Progetto speciale cardio-oncologia 2018 Russo A, Barbieri E, Barni S,…
-
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors:…
-
Effectiveness and Safety of LMWH Treatment in Patients With Cancer Diagnosed With Non-High-Risk Venous Thromboembolism:…
-
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) – Cancer-Associated Venous Thromboembolic Disease Streiff MB,…